Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Cyber Resilience Act Should Include Medtech, Says Data Protection Watchdog

Executive Summary

The European Commission’s decision to exclude medical devices from the scope of its proposed Cyber Resilience Act was praised by industry, but this could all change, as the EU’s data protection supervisor argues that medtech should be included in the legislation.

You may also be interested in...



Cybersecurity Skills Shortage In EU ‘Untenable’ Warns Medtech Trade Body

EU medtech companies are subject to many legislative requirements that ensure devices are cybersecure, but more investment in digital literacy is needed to keep Europe safe from cyber breaches, MedTech Europe says in a new policy paper.

EU Digital Tech Trade Body Weighs In On Medical Device ‘Over-Regulation’ Risk

While the European Health Data Space and its objectives should be a positive regulatory development for the EU health sector, DIGITALEUROPE stresses that the risk of counterproductive conflicts with other proposed laws around AI and data must be addressed.

How Harmonized Standards Are The Answer To EU Notified Body Cybersecurity Work

Few cybersecurity experts are available to assist during conformity assessments for medical devices, TEAM-NB has said. In light of this, its cybersecurity position paper recommends actions that will help notified bodies in their assessments.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT146056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel